Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)GlobeNewsWire • 02/23/26
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for DecadesThe Motley Fool • 02/22/26
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise InvestmentsReuters • 02/20/26
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular programReuters • 02/18/26
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide TherapeuticsGlobeNewsWire • 02/18/26
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)GlobeNewsWire • 02/18/26
NVS Reports Positive Late-Stage Data on Kidney Disease Drug VanrafiaZacks Investment Research • 02/13/26
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathyGlobeNewsWire • 02/13/26
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/04/26
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025GlobeNewsWire • 02/04/26
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 01/30/26
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's DiseaseZacks Investment Research • 01/19/26
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare PlanZacks Investment Research • 01/19/26